Investor Alert: Pomerantz Law Firm Investigates Sanara MedTech for Potential Securities Fraud
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Sanara MedTech, Inc. (NASDAQ: SMTI) and its officers following the discontinuation of its Tissue Health Plus program in November 2025, which led to a $31.2 million net loss from discontinued operations and caused the stock price to drop 24.7%.
Tickers: $SMTI
Topics: corporate_governance investor_protection stock_price_drop